Forward P/S Multiple: ClearPoint Neuro Inc. (CLPT)
The forward EV/Revenue multiple for ClearPoint Neuro, Inc. (CLPT) reflects market expectations for B2B neuronavigation system sales. The current parameter stands at 6.00, which correlates with the company's role as the creator of the foundational ecosystem for precision neuro-oncology. Current deliveries of stereotactic equipment via biotech partnerships support the share price increase, while regulatory risks are already priced into the asset.
Summary analytical data breakdowns for clearpointneuro.com (CLPT)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital ClearPoint Neuro, Inc.|CLPT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital ClearPoint Neuro|CLPT - Company Aggregate Debts|Debt to Book Capitalization Ratio ClearPoint Neuro, Inc.|CLPT - Company Long-Term Debt|Company Current Liabilities ClearPoint Neuro|Quick Ratio clearpointneuro.com
- financial results and valuation multiples details:
CLPT - Company Net Income|Expected Profit ClearPoint Neuro, Inc.|CLPT - Market Cap to Net Income Ratio|Projected Price to Earnings ClearPoint Neuro|CLPT - PEG Multiple|EV/EBITDA Multiple ClearPoint Neuro, Inc.|CLPT - Operating income before deduction of amortization|Earnings per share for the last twelve months ClearPoint Neuro|CLPT - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months clearpointneuro.com|CLPT - Net earnings per share growth this year|Earnings growth forecast for next year ClearPoint Neuro, Inc.
- sales and revenue indicators:
Fundamental company analysis:CLPT (ClearPoint)
Forward P/S determines the market value of an asset relative to projected revenue, allowing an investor to assess the extent of overpayment for future cash flows. The future P/S dynamics of ClearPoint Neuro, Inc. (CLPT) reflect market expectations for the scaling of robotic neuronavigation systems, where an increasing ratio confirms capital's bet on the expansion of high-precision hardware complexes in neurosurgery.
Who ClearPoint Neuro, Inc. competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Corp) - Forward Price-to-Revenue Multiple|IRADIMED Inc. - Forward Price to Sales|EMBC (Embecta Corp.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tandemdiabetes.com TNDM|Price-to-Projected Revenue Ratio Axogen (AXGN)|SI-BONE Inc (SIBN) - Projected Price to Revenue|Orthofix International - Forward Price-to-Revenue Multiple|Forward P/S Multiple Bioventus Global BVS|OrthoPediatrics Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio treace.com TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CARL (Carlsmed, Inc.)|Price-to-Projected Revenue Ratio RxSight Corp|Forward Price-to-Revenue Multiple Stereotaxis Corporation (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical International - Price to Expected Revenue Ratio|VANI: Forward P/S Multiple|Forward Price-to-Revenue Multiple Xtant Medical|Price-to-Projected Revenue Ratio NeuroOne Medical Technologies Corporation|Price-to-Projected Revenue Ratio MODD|Forward P/S Multiple MYO|COCH - Market Cap to Future Revenue Ratio|Forward P/S Multiple VVOS (Vivos Therapeutics)|Forward P/S Multiple envveno.com NVNO|SINT - Price-to-Projected Revenue Ratio|Forward Price to Sales TNON (Tenon Medical Inc.)|ReWalk Robotics Ltd (LFWD) - Price-to-Projected Revenue Ratio|Future Price to Revenue AMIX (Autonomix Medical)|Price-to-Projected Revenue Ratio INVO Fertility Inc|Market Cap to Future Revenue Ratio bonebiologics.com BBLG|Forward P/S Multiple AXNX|Market Cap to Expected Sales Ratio BIOLASE Inc.|Price-to-Projected Revenue Ratio Dynatronics DYNT|FNA: Market Cap to Projected Revenue|INVO: Forward Price-to-Revenue Multiple
